Repligen
RGEN
₹10,911
Share price
4.72%
Change (1 day)
-5.58%
Change (1 year)
Categories
Repligen (RGEN) - Cash on Hand
Cash on Hand as of March 2025 : ₹60.71 Billion
According to Repligen
's latest financial reports the company has ₹60.71 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Repligen - Cash on Hand chart (from 1996 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | ₹64.97 B | 3.88% |
| 2023-12-31 | ₹62.54 B | 21.18% |
| 2022-12-31 | ₹51.61 B | 14.85% |
| 2021-12-31 | ₹44.94 B | -14.33% |
| 2020-12-31 | ₹52.45 B | 39.22% |
| 2019-12-31 | ₹37.68 B | 178.03% |
| 2018-12-31 | ₹13.55 B | 22.15% |
| 2017-12-31 | ₹11.09 B | 15.15% |
| 2016-12-31 | ₹9.63 B | 101.99% |
| 2015-12-31 | ₹4.76 B | 28.75% |
| 2014-12-31 | ₹3.70 B | -2.69% |
| 2013-12-31 | ₹3.80 B | 73.59% |
| 2012-12-31 | ₹2.19 B | |
| 2011-03-31 | ₹2.20 B | -6.92% |
| 2010-03-31 | ₹2.36 B | -4.04% |
| 2009-03-31 | ₹2.46 B | 23.78% |
| 2008-03-31 | ₹1.99 B | 104.22% |
| 2007-03-31 | ₹0.97 B | 15.44% |
| 2006-03-31 | ₹0.84 B | 13.07% |
| 2005-03-31 | ₹0.74 B | 23.66% |
| 2004-03-31 | ₹0.60 B | -18.03% |
| 2003-03-31 | ₹0.73 B | -27.42% |
| 2002-03-31 | ₹1.01 B | -8.89% |
| 2001-03-31 | ₹1.11 B | -24.79% |
| 2000-03-31 | ₹1.48 B | 959.72% |
| 1999-03-31 | ₹0.14 B | -24.6% |
| 1998-03-31 | ₹0.18 B | 47.95% |
| 1997-03-31 | ₹0.12 B | -46.86% |
| 1996-03-31 | ₹0.23 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novavax NVAX | ₹63.69 B | 4.91% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | ₹110.79 B | 82.48% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | ₹82.15 B | 35.32% | 🇺🇸 USA |
 General Electric GE | ₹1.167 T | 1,822.61% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | ₹517.86 B | 752.95% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | ₹1.025 T | 1,589.83% | 🇺🇸 USA |
 Pfizer PFE | ₹1.507 T | 2,383.55% | 🇺🇸 USA |
 Bio-Techne TECH | ₹12.24 B | -79.82% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | ₹2.19 B | -96.39% | 🇺🇸 USA |
 Charles River Laboratories
CRL | ₹19.97 B | -67.10% | 🇺🇸 USA |